Trials / Completed
CompletedNCT02553928
Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With Alzheimer
Interventional, Randomised, Double-blind, Study to Evaluate the Safety and Tolerability of Once Daily Versus Twice Daily Memantine Treatment in Patients With Dementia of Alzheimer's Type and MMSE Range 5 - 18
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of the safety and tolerability of a 20 mg once daily dose of memantine compared with 10 mg given twice daily in patients with dementia of Alzheimer's type and MMSE range 5-18.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Memantine (once daily) | |
| DRUG | Memantine (twice daily) |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2016-07-01
- Completion
- 2016-07-01
- First posted
- 2015-09-18
- Last updated
- 2019-03-14
- Results posted
- 2019-03-14
Locations
6 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02553928. Inclusion in this directory is not an endorsement.